Literature DB >> 1849151

Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.

S Gupta1, J Kim, S Gollapudi.   

Abstract

Itraconazole is a recently developed triazole antifungal agent that inhibits cell membrane sterol biosynthesis. Itraconazole, in a dose-dependent manner, enhanced intracellular accumulation of daunorubicin and reversed the drug resistance in murine leukemia P388/ADR cells. In addition, itraconazole corrected the altered plasma membrane potentials of P388/ADR cells. The concentrations of itraconazole that reversed drug resistance are comparable to the plasma levels achieved by therapeutic dosage used in the treatment of fungal infections. Therefore, itraconazole is a potential candidate for in vivo use to reverse multidrug resistance in cancer with added benefit of its antifungal property.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1849151      PMCID： PMC295200          DOI： 10.1172/JCI115154

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  18 in total

1.  Pharmacokinetics of itraconazole following oral administration to normal volunteers.

Authors:  T C Hardin; J R Graybill; R Fetchick; R Woestenborghs; M G Rinaldi; J G Kuhn
Journal:  Antimicrob Agents Chemother       Date:  1988-09       Impact factor: 5.191

Review 2.  Resistance to multiple chemotherapeutic agents in human cancer cells.

Authors:  M M Gottesman; I Pastan
Journal:  Trends Pharmacol Sci       Date:  1988-02       Impact factor: 14.819

3.  First International Symposium on Itraconazole. Oaxaca, Mexico, October 7-8, 1985. Proceedings.

Authors: 
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

Review 4.  P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins.

Authors:  P F Juranka; R L Zastawny; V Ling
Journal:  FASEB J       Date:  1989-12       Impact factor: 5.191

5.  Ketoconazole and cyclosporin.

Authors:  H Dieperink; J Møller
Journal:  Lancet       Date:  1982-11-27       Impact factor: 79.321

Review 6.  Mechanism of multidrug resistance.

Authors:  G Bradley; P F Juranka; V Ling
Journal:  Biochim Biophys Acta       Date:  1988-08-03

7.  Correction of altered plasma membrane potentials. A possible mechanism of cyclosporin A and verapamil reversal of pleiotropic drug resistance in neoplasia.

Authors:  B Vayuvegula; L Slater; J Meador; S Gupta
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 8.  Pharmacological modulators of DNA-interactive antitumor drugs.

Authors:  J S Lazo; R R Bahnson
Journal:  Trends Pharmacol Sci       Date:  1989-09       Impact factor: 14.819

9.  Treatment of mycoses with itraconazole.

Authors:  R M Tucker; P L Williams; E G Arathoon; D A Stevens
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

10.  Efficacies of four antifungal agents in experimental murine sporotrichosis.

Authors:  V L Kan; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191
View more
  14 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Interaction of common azole antifungals with P glycoprotein.

Authors:  Er-jia Wang; Karen Lew; Christopher N Casciano; Robert P Clement; William W Johnson
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Pharmacokinetic interaction between itraconazole and ceftriaxone in Yucatan miniature pigs.

Authors:  A Cavalier; D Levêque; J D Peter; J Salmon; H Elkhaïli; Y Salmon; P Nobelis; J Geisert; H Monteil; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Repurposing itraconazole as an anticancer agent.

Authors:  Hiroshi Tsubamoto; Tomoko Ueda; Kayo Inoue; Kazuko Sakata; Hiroaki Shibahara; Takashi Sonoda
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

5.  Repurposing itraconazole for the treatment of cancer.

Authors:  Rachel Pounds; Sarah Leonard; Christopher Dawson; Sean Kehoe
Journal:  Oncol Lett       Date:  2017-07-10       Impact factor: 2.967

6.  Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer.

Authors:  Thiago S Lima; Luciano O Souza; Diego Iglesias-Gato; Johanna Elversang; Flemming Steen Jørgensen; Tuula Kallunki; Martin A Røder; Klaus Brasso; José M A Moreira
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

7.  Itraconazole and multidrug resistance: possible effects on remission rate and disease-free survival in acute leukemia.

Authors:  G Vreugdenhil; J M Raemaekers; B J van Dijke; B E de Pauw
Journal:  Ann Hematol       Date:  1993-09       Impact factor: 3.673

8.  Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.

Authors:  A Böhme; A Ganser; D Hoelzer
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

9.  Reversal effect of itraconazole on adriamycin and etoposide resistance in human leukemia cells.

Authors:  M Kurosawa; M Okabe; N Hara; K Kawamura; S Suzuki; K Sakurada; M Asaka
Journal:  Ann Hematol       Date:  1996-01       Impact factor: 3.673

10.  P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier.

Authors:  T Miyama; H Takanaga; H Matsuo; K Yamano; K Yamamoto; T Iga; M Naito; T Tsuruo; H Ishizuka; Y Kawahara; Y Sawada
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.